sweetmama
06-16-05, 03:03 PM
All of you super smart chemical peeps please tell me what, if any, concerns we should have about the drugs that have been banned with close properties to amphetamine and the effects of taking amphetamine salts for ADD/ADHD. Any responses to the article below is wanted:)Thanks!
http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=Anorectic&gwp=8&curtab=2222_1
Used on a short term basis clinically to treat obesity (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=Obesity&gwp=8&curtab=2222_1), some appetite suppressants are also available over the counter (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=Over-the-counter+substance&gwp=8&curtab=2222_1). Drugs (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=Drug&gwp=8&curtab=2222_1) of this class are frequently stimulants (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=Stimulant&gwp=8&curtab=2222_1) of the phenethylamine (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=Phenethylamine&gwp=8&curtab=2222_1) family, related to amphetamine (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=Amphetamine&gwp=8&curtab=2222_1) (speed). Indeed, amphetamine (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=Amphetamine&gwp=8&curtab=2222_1) itself was sold commercially as an appetite suppressant until it was outlawed in most parts of the world in the late 1950s (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=1950&gwp=8&curtab=2222_1) due to increasing exploitation of its stimulant (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=Stimulant&gwp=8&curtab=2222_1) properties ("abuse"). Many amphetamines (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=Amphetamine&gwp=8&curtab=2222_1) produce side effects including addiction (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=Addiction&gwp=8&curtab=2222_1), tachycardia (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=Tachycardia&gwp=8&curtab=2222_1) and hypertension (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=Hypertension&gwp=8&curtab=2222_1), making prolonged unsupervised use dangerous.
Epidemics (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=Epidemic&gwp=8&curtab=2222_1) of fatal pulmonary hypertension (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=Pulmonary+hypertension&gwp=8&curtab=2222_1) and heart valve damage associated with anorectic agents have led to the withdrawal of products from the market. This was the case with aminorex in the 1960s (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=1960s&gwp=8&curtab=2222_1), and again in the 1990s (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=1990s&gwp=8&curtab=2222_1) with fenfluramine (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=Fenfluramine&gwp=8&curtab=2222_1) (see: Fen-phen (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=Fen-phen&gwp=8&curtab=2222_1)). Likewise, association of the related appetite suppressant phenylpropanolamine (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=Phenylpropanolamine&gwp=8&curtab=2222_1) with hemorrhagic stroke (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=Cerebrovascular+accident&gwp=8&curtab=2222_1) led the FDA (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=Food+and+Drug+Administration&gwp=8&curtab=2222_1) to request its withdrawal from the market in the United States (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=United+States&gwp=8&curtab=2222_1) in 2000 (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=2000&gwp=8&curtab=2222_1), and similar concerns regarding ephedrine (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=Ephedrine&gwp=8&curtab=2222_1) resulted in an FDA (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=Food+and+Drug+Administration&gwp=8&curtab=2222_1) ban on its inclusion in dietary supplements, in 2004 (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=2004&gwp=8&curtab=2222_1).
http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=Anorectic&gwp=8&curtab=2222_1
Used on a short term basis clinically to treat obesity (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=Obesity&gwp=8&curtab=2222_1), some appetite suppressants are also available over the counter (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=Over-the-counter+substance&gwp=8&curtab=2222_1). Drugs (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=Drug&gwp=8&curtab=2222_1) of this class are frequently stimulants (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=Stimulant&gwp=8&curtab=2222_1) of the phenethylamine (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=Phenethylamine&gwp=8&curtab=2222_1) family, related to amphetamine (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=Amphetamine&gwp=8&curtab=2222_1) (speed). Indeed, amphetamine (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=Amphetamine&gwp=8&curtab=2222_1) itself was sold commercially as an appetite suppressant until it was outlawed in most parts of the world in the late 1950s (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=1950&gwp=8&curtab=2222_1) due to increasing exploitation of its stimulant (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=Stimulant&gwp=8&curtab=2222_1) properties ("abuse"). Many amphetamines (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=Amphetamine&gwp=8&curtab=2222_1) produce side effects including addiction (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=Addiction&gwp=8&curtab=2222_1), tachycardia (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=Tachycardia&gwp=8&curtab=2222_1) and hypertension (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=Hypertension&gwp=8&curtab=2222_1), making prolonged unsupervised use dangerous.
Epidemics (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=Epidemic&gwp=8&curtab=2222_1) of fatal pulmonary hypertension (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=Pulmonary+hypertension&gwp=8&curtab=2222_1) and heart valve damage associated with anorectic agents have led to the withdrawal of products from the market. This was the case with aminorex in the 1960s (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=1960s&gwp=8&curtab=2222_1), and again in the 1990s (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=1990s&gwp=8&curtab=2222_1) with fenfluramine (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=Fenfluramine&gwp=8&curtab=2222_1) (see: Fen-phen (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=Fen-phen&gwp=8&curtab=2222_1)). Likewise, association of the related appetite suppressant phenylpropanolamine (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=Phenylpropanolamine&gwp=8&curtab=2222_1) with hemorrhagic stroke (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=Cerebrovascular+accident&gwp=8&curtab=2222_1) led the FDA (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=Food+and+Drug+Administration&gwp=8&curtab=2222_1) to request its withdrawal from the market in the United States (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=United+States&gwp=8&curtab=2222_1) in 2000 (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=2000&gwp=8&curtab=2222_1), and similar concerns regarding ephedrine (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=Ephedrine&gwp=8&curtab=2222_1) resulted in an FDA (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=Food+and+Drug+Administration&gwp=8&curtab=2222_1) ban on its inclusion in dietary supplements, in 2004 (http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=2004&gwp=8&curtab=2222_1).